Safety and Efficacy of (177)Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing (223)Radium-Dichloride

SIMPLE SUMMARY: The alpha emitter (223)Radium-dichloride ((223)Ra) and the beta emitter (177)Lutetium ((177)Lu) targeting the prostate-specific membrane antigen (PSMA) are sequentially used for therapy of advanced bone-metastatic castration-resistant prostate cancer. Despite routine performance in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumgarten, Justus, Groener, Daniel, Nguyen Ngoc, Christina, Mader, Nicolai, Chaurasia, Maximilian, Davis, Karen, Wichert, Jennifer, Chun, Felix K. H., Tselis, Nikolaos, Happel, Christian, Grünwald, Frank, Sabet, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833613/
https://www.ncbi.nlm.nih.gov/pubmed/35158825
http://dx.doi.org/10.3390/cancers14030557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833613/
https://www.ncbi.nlm.nih.gov/pubmed/35158825
http://dx.doi.org/10.3390/cancers14030557

Ejemplares similares